Display options
Cite
Louis ED. Treatment of Essential Tremor: Are there Issues We are Overlooking?. Front Neurol. 2012;2:91doi: 10.3389/fneur.2011.00091.
Louis, E. D. (2011). Treatment of Essential Tremor: Are there Issues We are Overlooking?. Frontiers in neurology, 291. https://doi.org/10.3389/fneur.2011.00091
Louis, Elan D. "Treatment of Essential Tremor: Are there Issues We are Overlooking?." Frontiers in neurology vol. 2 (2011): 91. doi: https://doi.org/10.3389/fneur.2011.00091
Louis ED. Treatment of Essential Tremor: Are there Issues We are Overlooking?. Front Neurol. 2012 Jan 13;2:91. doi: 10.3389/fneur.2011.00091. eCollection 2011. PMID: 22275907; PMCID: PMC3257846.
Copy Download .nbib Format: NLM
Share it on

Front Neurol. 2012 Jan 13;2:91. doi: 10.3389/fneur.2011.00091. eCollection 2011.

Treatment of Essential Tremor: Are there Issues We are Overlooking?.

Frontiers in neurology

Elan D Louis

Affiliations

  1. Gertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University New York, NY, USA.

PMID: 22275907 PMCID: PMC3257846 DOI: 10.3389/fneur.2011.00091

Abstract

BACKGROUND: Essential tremor (ET) is one of the most common neurological diseases. Although a large number of medications have been tested, there are only two first-line medications, primidone and propranolol, which is a situation that has not changed in approximately 30 years. Several recent reviews have summarized the current pharmacotherapeutic options for ET and the approach to the management of ET patients. Yet there remain a number of important issues, both scientific and clinical, that have not been broached in the literature and that have therapeutic implications.

OBJECTIVES: To introduce several clinical and scientific issues that have not formally entered the published literature on the treatment of ET.

METHODS: In September 2011, materials for this article were gathered during a literature search of PubMed using the following terms: ET, clinical, clinical trial, treatment, medications, therapeutics. English-language articles were selected for further review.

RESULTS: The paper focuses on several topics that have received scant or no discussion in the published literature on ET therapeutics. These topics are as follows: the nature of the underlying disease pathophysiology, the presence of pathological heterogeneity, the complexity of cellular and neurochemical changes which may be underlying this disorder, the presence of clinical heterogeneity, the selection of treatment endpoints, the effects of diagnostic uncertainty, the presence of cognitive and psychiatric features in ET, the identification of possible modifiable risk factors, and the absence of any neuroprotective therapies.

CONCLUSION: The author has identified several topics that have received scant or no discussion in the published literature on ET therapeutics. Further discussion of the issues raised here may lead to improvements in clinical trial methodologies as well as facilitate the development of fresh approaches to pharmacotherapy.

Keywords: clinical; essential tremor; pharmacology; treatment

References

  1. Arch Neurol. 2006 Aug;63(8):1100-4 - PubMed
  2. Neurology. 2006 Jan 10;66(1):69-74 - PubMed
  3. Mult Scler. 2008 Sep;14(8):1026-30 - PubMed
  4. Eur J Neurol. 2010 Jun 1;17(6):882-4 - PubMed
  5. Mov Disord. 2008 May 15;23(7):993-997 - PubMed
  6. Curr Neurol Neurosci Rep. 2008 Jul;8(4):304-9 - PubMed
  7. Neurology. 2000 Jun 27;54(12):2342-4 - PubMed
  8. Nat Clin Pract Neurol. 2007 May;3(5):240-1 - PubMed
  9. Neurology. 2003 Dec 23;61(12):1804-6 - PubMed
  10. Brain. 2007 Dec;130(Pt 12):3297-307 - PubMed
  11. Arch Neurol. 2006 Aug;63(8):1189-93 - PubMed
  12. Mov Disord. 2006 Aug;21(8):1066-72 - PubMed
  13. Nat Clin Pract Neurol. 2006 Nov;2(11):629-35; quiz 1 p following 635 - PubMed
  14. Drug News Perspect. 2007 Jul-Aug;20(6):407-12 - PubMed
  15. Lancet. 2009 Mar 14;373(9667):929-40 - PubMed
  16. Neurology. 2006 May 23;66(10):1500-5 - PubMed
  17. BMJ. 1994 Jun 25;308(6945):1663-7 - PubMed
  18. Expert Opin Drug Saf. 2005 Sep;4(5):899-913 - PubMed
  19. Arch Neurol. 1999 Apr;56(4):475-80 - PubMed
  20. Parkinsonism Relat Disord. 2009 Aug;15(7):535-8 - PubMed
  21. Mov Disord. 2007 Jan 15;22(2):279-82 - PubMed
  22. Clin Neuropharmacol. 1990 Feb;13(1):67-76 - PubMed
  23. Mov Disord. 2008 Oct 15;23(13):1955-6 - PubMed
  24. Expert Rev Cardiovasc Ther. 2009 Jun;7(6):627-36 - PubMed
  25. Mov Disord. 2001 Sep;16(5):914-20 - PubMed
  26. Eur J Neurol. 2002 Mar;9(2):143-51 - PubMed
  27. J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):47-52 - PubMed
  28. Am J Psychiatry. 2002 Aug;159(8):1306-14 - PubMed
  29. Mov Disord. 2008 Jan 30;23(2):195-9 - PubMed
  30. Mov Disord. 2004 Oct;19(10):1163-8 - PubMed
  31. Brain. 1994 Aug;117 ( Pt 4):805-24 - PubMed
  32. Neurology. 2001 Sep 11;57(5):785-90 - PubMed
  33. Mov Disord. 1998 Jan;13(1):78-83 - PubMed
  34. Arch Neurol. 2002 Jan;59(1):102-12 - PubMed
  35. Mov Disord. 2002 Mar;17(2):313-6 - PubMed
  36. Mov Disord. 2003 Apr;18(4):432-6 - PubMed
  37. Parkinsonism Relat Disord. 2010 Dec;16(10):661-5 - PubMed
  38. Acta Neurol Scand. 2008 Dec;118(6):387-94 - PubMed
  39. Med Princ Pract. 2010;19(1):1-12 - PubMed
  40. J Neurosurg. 2008 Jan;108(1):111-7 - PubMed
  41. Ann Neurol. 2011 Feb;69(2):269-81 - PubMed
  42. Nat Rev Neurol. 2011 May;7(5):273-82 - PubMed
  43. Mov Disord. 1994 Mar;9(2):193-6 - PubMed
  44. Mov Disord. 2006 Aug;21(8):1114-8 - PubMed
  45. Neurology. 2007 Nov 20;69(21):1982-9 - PubMed
  46. BMC Neurol. 2005 Dec 10;5:24 - PubMed
  47. Neurology. 2009 Aug 25;73(8):621-5 - PubMed
  48. Mov Disord. 2006 Apr;21(4):441-5 - PubMed
  49. Mov Disord. 2007 Aug 15;22(11):1573-80 - PubMed
  50. Alcohol Clin Exp Res. 2007 Oct;31(10):1738-45 - PubMed
  51. J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1038-40 - PubMed
  52. Mov Disord. 2009 Mar 15;24(4):626-7 - PubMed
  53. Neurotherapeutics. 2008 Apr;5(2):331-8 - PubMed
  54. J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):1012-3 - PubMed
  55. N Engl J Med. 2000 Feb 17;342(7):461-8 - PubMed
  56. Arch Neurol. 2009 Oct;66(10):1202-8 - PubMed
  57. Arch Neurol. 1988 Mar;45(3):260-2 - PubMed
  58. Brain. 1949 Jun;72(Pt. 2):113-39 - PubMed
  59. Mov Disord. 2009 Apr 15;24(5):647-54 - PubMed
  60. Eur J Neurol. 2007 Oct;14(10):1138-46 - PubMed
  61. Neurotherapeutics. 2008 Apr;5(2):226-36 - PubMed
  62. Neurology. 2006 Jun 13;66(11):1756-9 - PubMed
  63. Ann Neurol. 2002 Mar;51(3):407 - PubMed
  64. J Neurol. 2001 May;248(5):399-402 - PubMed
  65. Neurology. 2005 Jun 28;64(12):2008-20 - PubMed
  66. Mov Disord. 1998 May;13(3):465-7 - PubMed
  67. Nat Clin Pract Neurol. 2006 Dec;2(12):666-78; quiz 2p following 691 - PubMed
  68. Headache. 2008 Jan;48(1):32-9 - PubMed
  69. Clin Neuropharmacol. 1984;7(1):83-8 - PubMed
  70. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):423-5 - PubMed
  71. Neurology. 2000;54(11 Suppl 4):S7 - PubMed
  72. J Am Soc Nephrol. 2007 Jun;18(6):1928-35 - PubMed
  73. Neurology. 2000;54(11 Suppl 4):S2-6 - PubMed
  74. Parkinsonism Relat Disord. 2003 Aug;9(6):341-7 - PubMed
  75. J Neural Transm (Vienna). 1996;103(5):555-60 - PubMed
  76. Neurology. 2005 Mar 22;64(6):1078-80 - PubMed
  77. J Neurol. 2000 Dec;247(12):955-9 - PubMed
  78. Neuroepidemiology. 2007;28(3):181-5 - PubMed
  79. Mov Disord. 1998;13 Suppl 3:2-23 - PubMed
  80. Neuropsychiatr Dis Treat. 2009;5:577-95 - PubMed
  81. Neurology. 2008 Apr 15;70(16 Pt 2):1452-5 - PubMed
  82. Consult Pharm. 2006 Jul;21(7):563-75 - PubMed
  83. Neurology. 1991 Dec;41(12):1982-3 - PubMed
  84. Lancet. 2007 Apr 7;369(9568):1152-4 - PubMed
  85. Age Ageing. 2006 Jul;35(4):344-9 - PubMed
  86. Brain Res. 2008 Jul 24;1221:98-107 - PubMed
  87. CNS Drugs. 2008;22(12):1037-45 - PubMed
  88. Neurology. 1993 Sep;43(9):1690-2 - PubMed
  89. J Int Neuropsychol Soc. 2001 Jan;7(1):92-101 - PubMed
  90. Mov Disord. 1997 May;12(3):337-41 - PubMed
  91. Neurology. 1999 Nov 10;53(8):1774-80 - PubMed
  92. Neurol Clin. 2009 Aug;27(3):633-77, v - PubMed
  93. Neurol Clin. 2009 Aug;27(3):719-36, vi - PubMed
  94. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):958-61 - PubMed
  95. Arch Neurol. 2008 Jan;65(1):101-7 - PubMed
  96. J Neurol Neurosurg Psychiatry. 2009 May;80(5):494-7 - PubMed
  97. Mov Disord. 2009 Feb 15;24(3):437-40 - PubMed
  98. Med Clin (Barc). 2007 Nov 3;129(16):632-7 - PubMed
  99. Mov Disord. 2008 Jan 30;23(2):246-52 - PubMed
  100. J Neurol Neurosurg Psychiatry. 1981 Jul;44(7):650 - PubMed
  101. Mov Disord. 2001 Jan;16(1):140-3 - PubMed
  102. Parkinsonism Relat Disord. 2005 Sep;11(6):367-73 - PubMed
  103. Trans Am Neurol Assoc. 1971;96:66-8 - PubMed
  104. Cerebellum. 2005;4(1):62-73 - PubMed
  105. Mov Disord. 2008 Jan 30;23(2):174-82 - PubMed
  106. Neurology. 2004 Jun 22;62(12):2320-2 - PubMed
  107. Brain. 2006 Nov;129(Pt 11):2840-55 - PubMed
  108. Neurology. 2006 Mar 14;66(5):672-7 - PubMed
  109. Arch Neurol. 2003 Mar;60(3):405-10 - PubMed
  110. Neuroepidemiology. 1997;16(3):124-33 - PubMed
  111. Brain. 2001 Nov;124(Pt 11):2278-86 - PubMed
  112. Arch Neurol. 2005 Jun;62(6):1004-7 - PubMed
  113. Curr Neurol Neurosci Rep. 2002 Jul;2(4):324-30 - PubMed
  114. Neuroepidemiology. 2009;32(3):208-14 - PubMed
  115. Lancet Neurol. 2011 Feb;10(2):148-61 - PubMed
  116. Curr Psychiatry Rep. 2000 Oct;2(5):421-6 - PubMed
  117. J Neuropathol Exp Neurol. 2010 Mar;69(3):262-71 - PubMed
  118. Expert Opin Biol Ther. 2001 May;1(3):467-79 - PubMed
  119. Eur J Neurol. 2008 Nov;15(11):1212-5 - PubMed
  120. Expert Rev Neurother. 2009 Dec;9(12):1781-9 - PubMed

Publication Types

Grant support